Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Euronext Paris  >  Ipsen    IPN   FR0010259150

IPSEN

(IPN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Ipsen : appoints Philippe Lopes-Fernandes as Executive Vice President, Chief Business Officer

share with twitter share with LinkedIn share with facebook
09/28/2020 | 11:18am EDT

PARIS - Ipsen (Euronext: IPN; ADR: IPSEY) today announced the appointment of Philippe Lopes-Fernandes as Executive Vice President, Chief Business Officer, effective 1 October 2020.

Based in Cambridge, Massachusetts, USA, he will be responsible for business development and alliance management, reporting directly to David Loew, CEO, Ipsen. Philippe will serve on the Executive Leadership Team.

'As Chief Business Officer, Philippe will play a crucial role in our external innovation strategy. The ELT and I are delighted to welcome Philippe to Ipsen and look forward to working closely with him. His extensive and impressive track record in international business development, his outstanding reputation and his ability to work closely with the scientific community around the world will be a tremendous asset as we continue to develop our position as a global biopharmaceutical leader via external innovation. I know Philippe will make significant contributions to our existing network of robust partnerships and will help us further strengthen our pipeline,' said David Loew, CEO, Ipsen.

'I'm excited to be joining Ipsen at this pivotal moment,' said Philippe Lopes-Fernandes. 'Working closely with David, the ELT and the Business Development team, I look forward to further strengthening Ipsen's alliances across its therapeutic areas to help achieve our vision of serving patients with high unmet medical needs.'

Prior to joining Ipsen, Philippe worked at Merck KGaA where he was the Senior Vice President, Global Head of Business Development and Alliance Management, based in Cambridge (US). Before that, he held a variety of roles at Merck KGaA in Business Development, Mergers & Acquisitions, Finance and Marketing in France, Portugal, Germany, the United States and Switzerland.

Philippe received his degree from the Institut Superieur de Gestion (ISG) in Paris in 1994. He is a French External Trade advisor (Conseiller du Commerce Exterieur) and board member of several companies.

About Ipsen

Ipsen is a global specialty-driven biopharmaceutical group focused on innovation and Specialty Care. The Group develops and commercializes innovative medicines in three key therapeutic areas - Oncology, Neuroscience, and Rare Diseases. Ipsen also has a well-established Consumer Healthcare business. With total sales over EUR2.5 billion in 2019, Ipsen sells more than 20 drugs in over 115 countries, with a direct commercial presence in more than 30 countries. Ipsen's R&D is focused on its innovative and differentiated technological platforms located in the heart of the leading biotechnological and life sciences hubs (Paris-Saclay, France; Oxford, UK; Cambridge, US). The Group has about 5,800 employees worldwide. Ipsen is listed in Paris (Euronext: IPN) and in the United States through a Sponsored Level I American Depositary Receipt program (ADR: IPSEY).

Ipsen's Forward Looking Statement

The forward-looking statements, objectives and targets contained herein are based on the Group's management strategy, current views and assumptions. Such statements involve known and unknown risks and uncertainties that may cause actual results, performance or events to differ materially from those anticipated herein. All of the above risks could affect the Group's future ability to achieve its financial targets, which were set assuming reasonable macroeconomic conditions based on the information available today. Use of the words 'believes', 'anticipates' and 'expects' and similar expressions are intended to identify forward-looking statements, including the Group's expectations regarding future events, including regulatory filings and determinations, and the outcome of this study or other studies. Moreover, the targets described in this document were prepared without taking into account external growth assumptions and potential future acquisitions, which may alter these parameters. These objectives are based on data and assumptions regarded as reasonable by the Group. These targets depend on conditions or facts likely to happen in the future, and not exclusively on historical data. Actual results may depart significantly from these targets given the occurrence of certain risks and uncertainties, notably the fact that a promising product in early development phase or clinical trial may end up never being launched on the market or reaching its commercial targets, notably for regulatory or competition reasons. The Group must face or might face competition from generic products that might translate into a loss of market share. Furthermore, the Research and Development process involves several stages each of which involves the substantial risk that the Group may fail to achieve its objectives and be forced to abandon its efforts with regards to a product in which it has invested significant sums. Therefore, the Group cannot be certain that favorable results obtained during preclinical trials will be confirmed subsequently during clinical trials, or that the results of clinical trials will be sufficient to demonstrate the safe and effective nature of the product concerned. There can be no guarantees a product will receive the necessary regulatory approvals or that the product will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements. Other risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of 6 pharmaceutical industry regulation and health care legislation; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the Group's ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the Group's patents and other protections for innovative products and the exposure to litigation, including patent litigation, and/or regulatory actions. The Group also depends on third parties to develop and market some of its products which could potentially generate substantial royalties; these partners could behave in such ways which could cause damage to the Group's activities and financial results. The Group cannot be certain that its partners will fulfil their obligations. It might be unable to obtain any benefit from those agreements. A default by any of the Group's partners could generate lower revenues than expected. Such situations could have a negative impact on the Group's business, financial position or performance. The Group expressly disclaims any obligation or undertaking to update or revise any forward-looking statements, targets or estimates contained in this press release to reflect any change in events, conditions, assumptions or circumstances on which any such statements are based, unless so required by applicable law. The Group's business is subject to the risk factors outlined in its registration documents filed with the French Autorite des Marches Financiers. The risks and uncertainties set out are not exhaustive and the reader is advised to refer to the Group's 2019 Universal Registration Document available on its website (www.ipsen.com).

Contact:

Tel: +33(0)1 58 33 58 96

Email: fanny.allaire@ipsen.com

(C) 2020 Electronic News Publishing, source ENP Newswire


Stocks mentioned in the article
ChangeLast1st jan.
IPSEN -1.49% 76.05 Real-time Quote.-2.28%
MERCK KGAA -1.67% 132.5 Delayed Quote.27.91%
share with twitter share with LinkedIn share with facebook
All news about IPSEN
10/27IPSEN : Disclosure of Transactions in Own Shares Between 10/19/2020 And 10/20/20..
BU
10/23IPSEN : delivers sales growth in the first nine months of 2020 despite the impac..
AQ
10/22IPSEN : Q3 2020 Sales Conference Call – Thursday, October 22, 2020
PU
10/22IPSEN : announces sales growth over the first 9 months of 2020
PU
10/22IPSEN : delivers sales growth in the first nine months of 2020 despite the impac..
PU
10/22IPSEN : Delivers Sales Growth in the First Nine Months of 2020 Despite the Impac..
BU
10/22IPSEN : 3rd quarter results
CO
10/20IPSEN : Disclosure of Transactions in Own Shares between 10/12/2020 and 10/16/20..
BU
10/16IPSEN : Q3 2020 Sales Conference Call – Thursday, October 22, 2020
PU
10/14BREAST CANCER AWARENESS MONTH : raising awareness with inspirational patient sto..
PU
More news
Financials
Sales 2020 2 651 M 3 101 M 3 101 M
Net income 2020 463 M 542 M 542 M
Net Debt 2020 728 M 852 M 852 M
P/E ratio 2020 13,9x
Yield 2020 1,32%
Capitalization 6 377 M 7 497 M 7 460 M
EV / Sales 2020 2,68x
EV / Sales 2021 2,35x
Nbr of Employees 5 807
Free-Float 42,0%
Chart IPSEN
Duration : Period :
Ipsen Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends IPSEN
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 17
Average target price 96,49 €
Last Close Price 77,20 €
Spread / Highest target 46,4%
Spread / Average Target 25,0%
Spread / Lowest Target 4,92%
EPS Revisions
Managers
NameTitle
David G. Loew Chief Executive Officer & Director
Marc M. P. de Garidel Non-Executive Chairman
Aymeric Le Chatelier Chief Financial Officer & Executive Vice President
Aidan Murphy Executive Vice President-Technical Operations
Howard Mayer Executive Vice President-Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
IPSEN-2.28%7 497
JOHNSON & JOHNSON-5.15%364 239
ROCHE HOLDING AG-6.18%276 926
PFIZER INC.-9.52%196 991
MERCK & CO., INC.-16.24%192 678
NOVARTIS AG-21.82%179 655